Form 4: Illumina CFO Ankur Dhingra Receives Stock and Performance Share Grants

Ankur Dhingra, SVP and CFO of Illumina, Inc., was granted restricted stock units and performance shares on May 6, 2024.

Summary

• Ankur Dhingra, the SVP and Chief Financial Officer of Illumina, Inc., received grants of restricted stock units and performance shares on May 6, 2024.
• The restricted stock units consist of 8,826 shares of common stock, vesting 25% annually over four years.
• Additionally, Dhingra received two grants of performance shares, each for 10,296 shares, contingent on Illumina's performance over the next three years.
• One performance share grant is based on the company's three-year average operating margin for fiscal years 2024-2026, and the other is based on relative total shareholder return for the fiscal year ending January 3, 2027.
• The number of shares issued for the performance share grants can range from 0% to 200% of the specified amount, depending on performance relative to pre-defined objectives.

Sentiment

Score: 7

Explanation: The document is neutral in tone, simply reporting the grant of stock and performance shares. The positive aspect is the alignment of the CFO's interests with shareholders through performance-based compensation.

Positives

• The grants of restricted stock units and performance shares align the CFO's interests with those of the shareholders.
• The performance-based vesting criteria for the performance shares incentivize strong financial performance and shareholder returns.
• The vesting schedule of the restricted stock units encourages long-term commitment from the CFO.

Risks

• The actual number of shares issued from the performance share grants is contingent on Illumina's future performance, which is subject to various market and operational risks.
• If Illumina does not meet the pre-defined objectives for operating margin and total shareholder return, the CFO may receive fewer shares than the maximum amount specified in the grants.

Future Outlook

The number of shares ultimately received from the performance share grants depends on Illumina's financial performance and shareholder returns over the next few years. The grants are designed to incentivize the CFO to drive value creation for the company and its shareholders.

Industry Context

Executive compensation packages often include a mix of salary, stock options, restricted stock units, and performance shares to attract and retain top talent. Performance-based equity grants are common in the biotech industry to align executive incentives with shareholder value creation.

Comparison to Industry Standards

• Comparing Illumina's executive compensation structure to companies like Thermo Fisher Scientific, Danaher, and Agilent Technologies would provide a benchmark for assessing the competitiveness and appropriateness of the grants.
• Reviewing proxy statements of these companies would reveal the typical mix of equity-based compensation and the performance metrics used for vesting.
• Analyzing the total shareholder return and operating margin performance of these companies would offer context for evaluating the difficulty of achieving the targets set for Illumina's performance share grants.

Stakeholder Impact

• Shareholders benefit from the alignment of executive compensation with company performance.
• Employees may be motivated by the company's focus on achieving performance targets.
• The grants do not have a direct impact on customers, suppliers, or creditors.

Next Steps

• Monitor Illumina's performance against the targets set for the performance share grants.
• Track the vesting of the restricted stock units over the next four years.
• Review future SEC filings to see if the CFO sells any of the shares acquired through these grants.

Key Dates